Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels
Stephen Kirnon, San Ramon, CA (US); Eric Freedland, Marblehead, MA (US); and Rajagopal V. Sekhar, Missouri City, TX (US)
Assigned to Societe des Produits Nestle S.A., Vevey (CH); and Baylor College of Medicine, Houston, TX (US)
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH); and BAYLOR COLLEGE OF MEDICINE, Houston, TX (US)
Filed on Dec. 15, 2022, as Appl. No. 18/082,133.
Application 18/082,133 is a division of application No. 17/175,111, filed on Apr. 7, 2022, granted, now 41,787,352.
Application 17/175,111 is a continuation of application No. 15/577,422, granted, now 10,952,982, issued on Mar. 23, 2021, previously published as PCT/US2016/034078, filed on May 25, 2016.
Claims priority of provisional application 62/167,433, filed on May 28, 2015.
1. A method of neutralizing or mitigating a drug-induced mitochondrial dysfunction or impairment for an individual, the method comprising providing to the individual an effective amount of a composition comprising glycine and N-acetylcysteine, wherein the drug-induced mitochondrial dysfunction or impairment is from.